Professional Summary
Education & Certifications
- Residency: UCSD Dept of Radiology (2014) CA
- Board Certification: American Board of Radiology, Diagnostic Radiology (2015)
- Fellowship: Stanford University Radiology Fellowships (2015) CA
-
- Board Certification: American Board of Nuclear Medicine, Nuclear Medicine (2015)
- Internship: University of Massachusetts Internal Medicine Residency (2009) MA
- PhD, California Institute of Technology, Computation and Neural Systems (2007)
- Medical Education: Tehran University of Medical Sciences (2000) Iran
Administrative Appointments
- Modality Director, Nuclear Medicine (2020 - Present)
-
Publications
-
Spectrum of Ga-68-DOTA TATE Uptake in Patients With Neuroendocrine Tumors
Moradi, F., Jamali, M., Barkhodari, A., Schneider, B., Chin, F., Quon, A., … Iagaru, A. (2016). Spectrum of Ga-68-DOTA TATE Uptake in Patients With Neuroendocrine Tumors. CLINICAL NUCLEAR MEDICINE, 41(6), E281–E287. -
Physiological distribution of Ga-68-DOTA-TATE: an atlas of standardized uptake values
Moradi, F., Minamimoto, R., Jamali, M., Barkhodari, A., Quon, A., Mittra, E., … Iagaru, A. (2015). Physiological distribution of Ga-68-DOTA-TATE: an atlas of standardized uptake values. JOURNAL OF NUCLEAR MEDICINE, 56(3). -
Prospective Evaluation of F-18-DCFPyL PET/CT and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer
Song, H., Harrison, C., Guja, K., Franc, B., Moradi, F., Davidzon, G., … Iagaru, A. (2019). Prospective Evaluation of F-18-DCFPyL PET/CT and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
-
Quantification of uptake in Ga-68-DOTATATE PET: Correlation between standardized uptake values and patient factors
Moradi, F., Guja, K., Aparici, C. M., & Iagaru, A. (2019). Quantification of uptake in Ga-68-DOTATATE PET: Correlation between standardized uptake values and patient factors. JOURNAL OF NUCLEAR MEDICINE, 60. -
Prospective Comparison of F-18-DCFPyL PET/CT with F-18-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer
Duan, H., Song, H., Baratto, L., Khalaf, M., Hatami, N., Franc, B., … Iagaru, A. (2019). Prospective Comparison of F-18-DCFPyL PET/CT with F-18-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Prospective evaluation of F-18- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels
Harrison, C., Song, H., Franc, B. L., Guja, K., Moradi, F., Davidzon, G., … Iagaru, A. (2019). Prospective evaluation of F-18- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement.
Toriihara, A., Nobashi, T., Baratto, L., Duan, H., Moradi, F., Park, S., … Iagaru, A. (2019). Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management.
Song, H., Harrison, C., Duan, H., Guja, K., Hatami, N., Franc, B., … Iagaru, A. (2019). Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation.
Girod, B. J., Guja, K. E., Davidzon, G., Chan, F., Zucker, E., Franc, B. L., … Aparici, C. M. (2020). Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation. Radiology Case Reports, 15(2), 117–19. -
Glucose-corrected standardized uptake value (SUVgluc) is the most accurate SUV parameter for evaluation of pulmonary nodules
Jahromi, A. H., Moradi, F., & Hoh, C. K. (2019). Glucose-corrected standardized uptake value (SUVgluc) is the most accurate SUV parameter for evaluation of pulmonary nodules. AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 9(5), 243–47. -
Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities.
Shaheen, S., Moradi, F., Gamino, G., & Kunz, P. L. (2020). Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Current Treatment Options in Oncology, 21(4), 25. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
Nakamoto, R., Zaba, L. C., Rosenberg, J., Reddy, S. A., Nobashi, T. W., Davidzon, G., … Franc, B. L. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging. -
Prevalence of Bone Metastases in Neuroendocrine Neoplasms by 68Ga DOTATATE PET Scan
Shaheen, S., Gardner, R., Sundaram, V., Hornbacker, K., Moradi, F., Wu, J., & Kunz, P. (2020). Prevalence of Bone Metastases in Neuroendocrine Neoplasms by 68Ga DOTATATE PET Scan. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Perfusion Scintigraphy in Diagnosis and Management of Thromboembolic Pulmonary Hypertension.
Moradi, F., Morris, T. A., & Hoh, C. K. (2019). Perfusion Scintigraphy in Diagnosis and Management of Thromboembolic Pulmonary Hypertension. Radiographics : a Review Publication of the Radiological Society of North America, Inc, 39(1), 169–185. -
Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET)
Duan, H., Ninatti, G., Girod, B., Ferri, V., Kunz, P. L., Fisher, G. A., … Mari, C. (2020). Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). JOURNAL OF CLINICAL ONCOLOGY, 38(4). -
Quantification of brain oxygen extraction and metabolism with [15O]-gas PET: A technical review in the era of PET/MRI.
Fan, A. P., An, H., Moradi, F., Rosenberg, J., Ishii, Y., Nariai, T., … Zaharchuk, G. (2020). Quantification of brain oxygen extraction and metabolism with [15O]-gas PET: A technical review in the era of PET/MRI. NeuroImage, 117136. -
Will FAPI PET/CT Replace FDG PET/CT in the Next Decade?-Counterpoint: No, not so fast!
Moradi, F., & Iagaru, A. (2020). Will FAPI PET/CT Replace FDG PET/CT in the Next Decade?-Counterpoint: No, not so fast! AJR. American Journal of Roentgenology. -
The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer.
Moradi, F., & Iagaru, A. (2020). The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer. Seminars in Nuclear Medicine, 50(5), 434–46. -
Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy.
Nakamoto, R., C Zaba, L., Rosenberg, J., Arani Reddy, S., W Nobashi, T., Ferri, V., … Lewis Franc, B. (2020). Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy. Molecular Imaging and Biology. -
INTERIM ANALYSIS RESULTS OF A PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING
Baratto, L., Song, H., Duan, H., Aparici, C. M., Hatami, N., Davidzon, G., … Iagaru, A. (2020). INTERIM ANALYSIS RESULTS OF A PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [18F]FDG PET/CT.
Guja, K. E., Brown, R., Girod, B., Song, H., Harrison, C., Franc, B. L., … Aparici, C. M. (2020). An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. -
Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution.
Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Franc, B. L., … Iagaru, A. (2020). Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Song, H., Kunz, P., Franc, B., Moradi, F., Fisher, G., Aparici, C. M., … Davidzon, G. (2020). Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)
Duan, H., Girod, B., Ninatti, G., Ferri, V., Kunz, P., Fisher, G., … Aparici, C. M. (2020). Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs). JOURNAL OF NUCLEAR MEDICINE, 61. -
Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
PSMA-and GRPR-targeted PET: Preliminary Results in Patients with Biochemically Recurrent Prostate Cancer
Baratto, L., Duan, H., Hatami, N., Song, H., Davidzon, G., Franc, B., … Iagaru, A. (2020). PSMA-and GRPR-targeted PET: Preliminary Results in Patients with Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Ga-68-PSMA-11 PET/MR Imaging before prostatectomy: correlation with surgical pathology and two-year follow up
Moradi, F., Baratto, L., Duan, H., Hatami, N., Davidzon, G., Sonn, G., & Iagaru, A. (2020). Ga-68-PSMA-11 PET/MR Imaging before prostatectomy: correlation with surgical pathology and two-year follow up. JOURNAL OF NUCLEAR MEDICINE, 61. -
The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval.
Nakamoto, R., Harrison, C., Song, H., Guja, K. E., Hatami, N., Nguyen, J., … Iagaru, A. (2021). The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval. Molecular Imaging and Biology. -
Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., … Franc, B. L. (2021). Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study.
Morris, M. J., Rowe, S. P., Gorin, M. A., Saperstein, L., Pouliot, F., Josephson, D. Y., … Pachynski, R. K. (2021). Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.
Baratto, L., Song, H., Duan, H., Aparici, C. M., Davidzon, G., Moradi, F., … Iagaru, A. (2020). A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., … Iagaru, A. (2021). PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Clinical Applications of PET/MR Imaging.
Moradi, F., Iagaru, A., & McConathy, J. (2021). Clinical Applications of PET/MR Imaging. Radiologic Clinics of North America, 59(5), 853–874. -
Prostate cancer: Molecular imaging and MRI.
Moradi, F., Farolfi, A., Fanti, S., & Iagaru, A. (2021). Prostate cancer: Molecular imaging and MRI. European Journal of Radiology, 143, 109893. -
PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING
Baratto, L., Song, H., Duan, H., Moradi, F., Davidzon, G., & Iagaru, A. (2021). PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES
Song, H., Nguyen, J., Moradi, F., Aparici, C. M., Franc, B., Davidzon, G., & Iagaru, A. (2021). PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Positron Emission Tomography and Molecular Imaging of Head and Neck Malignancies
Moradi, F. (2020). Positron Emission Tomography and Molecular Imaging of Head and Neck Malignancies. CURRENT RADIOLOGY REPORTS, 8(11). -
A Pilot Study of68Ga-PSMA11 PET/MRI and68GaRM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
Duan, H., Ferri, V., Ghanouni, P., Daniel, B., Hatami, N., Davidzon, G., … Iagaru, A. (2021). A Pilot Study of68Ga-PSMA11 PET/MRI and68GaRM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Perfusion Only Scans with and without SPECT/CT in the Era of COVID-19
Zhang, R., Moradi, F., Aparici, C. M., Davidzon, G., Nguyen, J., Iagaru, A., & Franc, B. (2021). Perfusion Only Scans with and without SPECT/CT in the Era of COVID-19. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
Moradi, F., Duan, H., Song, H., Davidzon, G. A., Chung, B. I., Thong, A. E., … Iagaru, A. (2022). 68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Correlation of 68Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
Duan, H., Baratto, L., Fan, R. E., Soerensen, S. J., Liang, T., Chung, B. I., … Iagaru, A. (2022). Correlation of 68Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Positron emission tomography/computed tomography differentiates resectable thymoma from anterior mediastinal lymphoma.
Byrd, C. T., Trope, W. L., Bhandari, P., Konsker, H. B., Moradi, F., Lui, N. S., … Shrager, J. B. (2022). Positron emission tomography/computed tomography differentiates resectable thymoma from anterior mediastinal lymphoma. The Journal of Thoracic and Cardiovascular Surgery. -
Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Moradi, F., … Aparici, C. M. (2022). Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Posttreatment FDG-PET/CT Hopkins criteria predict locoregional recurrence after definitive radiotherapy for oropharyngeal squamous cell carcinoma.
Miller, J. A., Moradi, F., Sundaram, V., Liang, R., Zhang, C., Nguyen, N. K., … Gensheimer, M. F. (2022). Posttreatment FDG-PET/CT Hopkins criteria predict locoregional recurrence after definitive radiotherapy for oropharyngeal squamous cell carcinoma. Head & Neck. -
A Pilot Study of Ga-68-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Sonn, G. A., … Iagaru, A. (2022). A Pilot Study of Ga-68-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Kunder, C., … Iagaru, A. (2022). A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Results of First Interim Analysis of 68Ga-NeoB and 68Ga-PSMA R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer
Duan, H., Song, H., Davidzon, G., Moradi, F., & Iagaru, A. (2022). Results of First Interim Analysis of 68Ga-NeoB and 68Ga-PSMA R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Retroperitoneal Inflammation Detected on FDG PET/CT in Patient on Long-Term Immunotherapy.
Khessib, T., Franc, B., Yang, E., & Moradi, F. (2023). Retroperitoneal Inflammation Detected on FDG PET/CT in Patient on Long-Term Immunotherapy. Clinical Nuclear Medicine. -
SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting.
Song, H., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., … Iagaru, A. (2023). SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting. European Journal of Nuclear Medicine and Molecular Imaging. -
Predicting FDG-PET Images From Multi-Contrast MRI Using Deep Learning in Patients With Brain Neoplasms.
Ouyang, J., Chen, K. T., Duarte Armindo, R., Davidzon, G. A., Hawk, K. E., Moradi, F., … Zaharchuk, G. (2023). Predicting FDG-PET Images From Multi-Contrast MRI Using Deep Learning in Patients With Brain Neoplasms. Journal of Magnetic Resonance Imaging : JMRI. -
Clinical Radiosynthesis and Translation of [18F]OP-801: A Novel Radiotracer for Imaging Reactive Microglia and Macrophages.
Jackson, I. M., Carlson, M. L., Beinat, C., Malik, N., Kalita, M., Reyes, S., … James, M. L. (2023). Clinical Radiosynthesis and Translation of [18F]OP-801: A Novel Radiotracer for Imaging Reactive Microglia and Macrophages. ACS Chemical Neuroscience. -
Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.
Duan, H., Davidzon, G. A., Moradi, F., Liang, T., Song, H., & Iagaru, A. (2023). Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET. European Journal of Nuclear Medicine and Molecular Imaging. -
Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer
Song, H., Sjostrand, K., Duan, H., Ferri, V., Aparici, C. M., Davidzon, G., … Iagaru, A. (2023). Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PET Imaging of Neuroinflammation in ALS Patients Using <SUP>18</SUP>F-OP-801, a Novel Nanoimaging Agent
Maricich, S. M., Korn, R., Lomen-Hoerth, C., So, Y., Oguno, B., Cleland, J. L., … Moradi, F. (2023). PET Imaging of Neuroinflammation in ALS Patients Using 18F-OP-801, a Novel Nanoimaging Agent. ANNALS OF NEUROLOGY. WILEY. -
Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET
Duan, H., Davidzon, G., Moradi, F., Liang, T., & Iagaru, A. (2023). Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Final Analysis of a Prospective, Single-center, Phase II/III Imaging Trial of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer
Duan, H., Moradi, F., Davidzon, G., Liang, T., & Iagaru, A. (2023). Final Analysis of a Prospective, Single-center, Phase II/III Imaging Trial of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Total and Anatomically Contextualized Quantitative 18F-DCFPyL PET at biochemical recurrence predicts subsequent biochemical progression free survival in prostate cancer patients
Song, H., Duan, H., Ferri, V., Na, S. J., Davidzon, G., Franc, B., … Iagaru, A. (2023). Total and Anatomically Contextualized Quantitative 18F-DCFPyL PET at biochemical recurrence predicts subsequent biochemical progression free survival in prostate cancer patients. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
A Case-Based Primer on FDG PET/CT for Imaging Cardiovascular Infections: Protocol, Interpretation, and Pitfalls.
Zhou, W., Moradi, F., Davidzon, G., Song, H., Grady, E., Nguyen, J., … Shah, J. (2023). A Case-Based Primer on FDG PET/CT for Imaging Cardiovascular Infections: Protocol, Interpretation, and Pitfalls. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Rapid dynamic reconstruction using list mode data for monitoring PET image quality accurately predicts final image noise and perceived quality
Moradi, F., Khalighi, M. M., Su, K.-H., Zhang, X., Wollenweber, S., Spangler-Bickell, M., … Iagaru, A. (2023). Rapid dynamic reconstruction using list mode data for monitoring PET image quality accurately predicts final image noise and perceived quality. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial.
Duan, H., Moradi, F., Davidzon, G. A., Liang, T., Song, H., Loening, A. M., … Iagaru, A. (2024). 68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. The Lancet. Oncology. -
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., … Iagaru, A. (2024). Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. -
Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
Duan, H., Song, H., Davidzon, G. A., Moradi, F., Liang, T., Loening, A., … Iagaru, A. (2024). Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Total and anatomically contextualized quantitative <SUP>18</SUP>F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer.
Song, H., Anand, A., Sjostrand, K., Ferri, V., Duan, H., Shah, J., … Iagaru, A. (2024). Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of <SUP>177</SUP>Lu-PSMA-617 treatment.
Leonio, M. I., Ferri, V., Duan, H., Shah, J., Moradi, F., Mari Aparici, C., … Iagaru, A. (2024). Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of 177Lu-PSMA-617 treatment. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
-
Quantification of uptake in Ga-68-DOTATATE PET: Correlation between standardized uptake values and patient factors
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
Nuclear Medicine and Molecular Imaging Stanford, CA
Stanford, CA
Nuclear Medicine and Molecular Imaging
300 Pasteur Drive, 2nd Floor C21
Stanford , CA 94305
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records